**SECTION 1: MODULE SPECIFICATIONS**

1. Title of the module

**Clinical Pharmacology (PHAR1042)**

1. School or partner institution which will be responsible for management of the module

**Medway School of Pharmacy**

1. Start date of the module

**October 2016**

1. The number of students expected to take the module

**30 students**

1. Modules to be withdrawn on the introduction of this proposed module and consultation with other relevant Schools and Faculties regarding the withdrawal

**None**

1. The level of the module (e.g. Certificate [C], Intermediate [I], Honours [H] or Postgraduate [M])

**H**

1. The number of credits and the ECTS value which the module represents

**15 credits (7.5)**

1. Which term(s) the module is to be taught in (or other teaching pattern)

**Term 1**

1. Prerequisite and co-requisite modules

**Pharmacokinetics**

**Cardiovascular Respiratory and Renal Pharmacology**

**Immunopharmacology and Microbiology**

**Endocrine and Gastrointestinal Pharmacology**

**Research Methods in Pharmacology**

**Neuropharmacology**

1. The programmes of study to which the module contributes

**BSc (Hons) in Physiology and Pharmacology**

1. The intended subject specific learning outcomes

On successful completion of this module, students will have demonstrated:

1. **Have a good understanding of evidence-based drug therapy and the significance of the randomised double-blind placebo controlled trial (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
2. **Understand what is meant by pharmacovigliance and pharmacoepidemiology (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
3. **Have an understanding of the possible sources of adverse drug interactions (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
4. **Understand the clinical pharmacology of the principal drugs used to treat infection and inflammation (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
5. **Understand how neuroactive drugs are used clinically in anaesthesia, pain management, and neurological disorders such as dementia, Parkinson’s disease, epilepsy and multiple sclerosis (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
6. **Understand the clinical use of cholinergic, anti-muscarinic, and adrenergic drugs (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
7. **Understand how the various classes of diuretics are used clinically (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
8. **Understand the use and application of antitussives and respiratory stimulants (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
9. **Understand the clinical use of pro-coagulant and anti-coagulant drugs (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3) .**
10. **Understand the clinical use and application of the various classes of cytotoxic drugs in the treatment of cancer (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
11. **Understand the clinical use and application of drugs that effect gastrointestinal motility (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
12. **Understand the clinical application of anti-diabetes agents and anti-thyroid drugs (POA1, POA2, POA3, POA5, POB1, POB2, POB3, POC4, POD1,POD3).**
13. The intended generic learning outcomes
14. **An ability to analyse, evaluate and correctly interpret data (POB1-5)**
15. **An ability to present and communicate data (POD2, POD3, POD4)**
16. **An ability to obtain and use information from a variety of sources as part of self-directed learning (POD1-6)**
17. **Time-management and organisational skills within the context of self-directed learning (POD1-6)**
18. A synopsis of the curriculum

* **Evaluation of drug effects in humans**
* **Unwanted drug effects and adverse drug reactions**
* **Infection and inflammation**
* **Nervous system**
* **Cardiorespiratory and renal systems**
* **Blood and neoplastic disease**
* **Gastrointestinal system**
* **Endocrine system and metabolic disorders**

1. Indicative Reading List

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **ISBN number** | **Author** | **Date** | **Title** | **Publisher** |
| **0702040843** | **Peter Bennett**  **Morris Brown**  **Pankaj Sharma** | **15 Sep 2010** | **Clinical Pharmacology** | **Elsevier** |

1. Learning and Teaching Methods, including the nature and number of contact hours and the total study hours which will be expected of students, and how these relate to achievement of the intended module learning outcomes

**Summary of Learning and Teaching Activities**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Lecture** | **Practical** | **MSCL/ CAL** | **Seminars** | **Private Study** | **Formal assessment** | **Total hours** |
| **20** | **6** | **63** | **2** | **56** | **1 x 3 hour exam** | **150** |

**Lectures** are intended to present the key points and relate directly to the learning objectives (above)

**Practicals** (laboratories/workshops) serve to reinforce material presented in the lectures and relate directly to the learning objectives.

**MSCL** serves to reinforce material presented in the lectures and practical components. They also form part of the self-directed learning for the student

**Revision seminars** offer the students an opportunity to ask further questions of the staff and reinforce key points.

**Private study** encompasses the revising all material presented in the lectures, laboratories, workshops, MSCL. Students should be able to work through the learning objectives (above) and identify key areas that require further revision

1. Assessment methods and how these relate to testing achievement of the intended module learning outcomes

|  |  |  |  |
| --- | --- | --- | --- |
| **Method of assessment** | **Learning outcomes assessed (POs & SSLOs)** | **Weighting** | **Outline details** |
| **Continuous assessment** | **All subject specific learning outcomes (SSLOs)**  **All generic learning outcomes** | **40%** | **Critical evaluation essay on a current published clinical trial** |
| **Examination** | **All subject specific learning outcomes (SSLOs)** | **60%** | **3 hour examination** |

**The pass mark for this module is 40%.**

1. Implications for learning resources, including staff, library, IT and space

**Additional laboratory resources may be required for this module.**

1. The School recognises and has embedded the expectations of current disability equality legislation, and supports students with a declared disability or special educational need in its teaching. Within this module we will make reasonable adjustments wherever necessary, including additional or substitute materials, teaching modes or assessment methods for students who have declared and discussed their learning support needs. Arrangements for students with declared disabilities will be made on an individual basis, in consultation with the University’s/Collaborative Partner’s (delete as applicable) disability/dyslexia support service, and specialist support will be provided where needed.
2. Campus(es) where module will be delivered:

**Medway School of Pharmacy, Medway Campus**

1. Partner College/Validated Institution:
2. University School responsible for the programme: **Medway School of Pharmacy**

**SECTION 2: MODULE IS PART OF A PROGRAMME OF STUDY IN A UNIVERSITY SCHOOL**

**Statement by the School Director of Learning and Teaching/School Director of Graduate Studies (as appropriate):** "I confirm I have been consulted on the above module proposal and have given advice on the correct procedures and required content of module proposals"

|  |  |
| --- | --- |
| ................................................................  Director of Learning and Teaching  Dr Buge Apampa | ..............................................  Date |

**Statement by the Head of School:** "I confirm that the School has approved the introduction of the module and, where the module is proposed by School staff, will be responsible for its resourcing"

|  |  |
| --- | --- |
| .................................................................  Head of School  Prof I Cumming. | ..............................................  Date |

**SECTION 3: MODULE IS PART OF A PROGRAMME IN A PARTNER COLLEGE OR VALIDATED INSTITUTION**

(Where the module is proposed by a Partner College/Validated Institution)

**Statement by the Nominated Officer of the College/Validated Institution** *(delete as applicable)***:** "I confirm that the College/Validated Institution*(delete as applicable)* has approved the introduction of the module and will be responsible for its resourcing"

|  |  |
| --- | --- |
| .................................................................  Nominated Responsible Officer of Partner College/Validated Institution  ………………………………………………….  Print Name  …………………………………………………..  Post | ..............................................  Date |

………………………………………….

Partner College/Validated Institution

Module Specification Template  
Last updated February 2013